Double-Blinded Drug Discovery

- Innovative protected open innovation model for validating (de-risking) new targets
- Enables projects to proceed measurably more efficiently and cost-effectively
- Accelerates technology transfer
- Potential for repositioning sunk programs and clinical candidates

DBD2 brings together new partners in academia and pharms via a new ‘try-before-you-buy’ licensing paradigm.

- Milestone-gated risk sharing

The LCGC Mission

LCGC is a transparent broker, driving innovative approaches for IP-protected resource sharing between pharms and universities. We provide a missing link for more cost-effective, productive public-private partnering.

We serve as an agent for solving challenges in hypothesis-driven drug discovery (i.e., chemical genomics). Our aim is to catalyze collaborative research between chemical-biology investigators at universities worldwide and R&D thought leaders in pharmaceutical companies.

www.limr.org/LCGC

Contact: Melvin Reichman, PhD  
Director, LIMR-LCGC  
100 E. Lancaster Avenue  
Wynnewood, PA 19096  
Phone: 484.476.8230  
reichmanm@mlhs.org
LCGC is an agent that bridges a gap in public-private partnering between academia and industry for advancing innovation.

DBD2 is a unique collaborative avenue for mining the latent value in pharma's chemical assets by leveraging the hugely parallel, basic and translational research network of bioassays in academia and biotech startups worldwide.

Our high-fidelity distribution system for large chemical collections directly into innovative drug-screening assays is unprecedented. A unique collaborative agreement template fosters productive licensing outcomes sans encumbrments. The IP of all parties is strongly protected, while allowing joint research to proceed unfettered by administrative roadblocks. In addition to our high throughput infrastructure and methods, we offers unique libraries that are unavailable elsewhere.

We make available assay-ready, orthogonally pooled screening plates that allow 500% more efficient HTS—so the assays can be run immediately at the home bench. Our approach may detect unexpected, combination-drug synergy in a radical new way.

Our objective is to accelerate technology transfer from academia to pharmaceutical companies at costs and attractive benefit-to-risk for all participants.